Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain inhibitory neurons (4144 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 521 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5283
Sealed predictions
- CNTNAP2 in dopamine neurons, braak+0.80 (p 0.009) → +0.29 (p 0.456)receipt 5291
Swarm cases
receipt 5291: CNTNAP2 in dopamine neurons, braak
- power
- full sample +0.60 (p 0.0086, n 18), 95% CI +0.18 to +0.83. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.67 (p 0.0025, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.67 (p 0.0025, n 18). not the mix.
- skeptic
- leave-one-out range +0.55 to +0.72, sign flips 0; without severely affected donors +0.60 (p 0.0086, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CNTNAP2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts